Ciramadol

Ciramadol

Ciramadol is a synthetic opioid analgesic developed in the late 1970s by the pharmaceutical company Eli Lilly. It is structurally related to other opioids such as tramadol and levorphanol, and has similar pharmacological effects.

Chemistry

Ciramadol is a synthetic opioid, meaning it is not derived from natural sources like the opium poppy. It is structurally similar to other synthetic opioids, including tramadol and levorphanol. The chemical structure of ciramadol includes a cyclohexane ring, which is a common feature in many opioid compounds.

Pharmacology

Like other opioids, ciramadol works by binding to and activating the mu-opioid receptor in the brain. This receptor is responsible for the pain-relieving effects of opioids. Ciramadol has been shown to have a high affinity for the mu-opioid receptor, meaning it binds strongly to this receptor and is therefore likely to produce significant analgesic effects.

Clinical Use

Ciramadol was developed as a potential treatment for moderate to severe pain. However, it has not been widely used in clinical practice. This may be due to a variety of factors, including the availability of other effective opioid analgesics and concerns about the potential for opioid addiction and misuse.

Side Effects

As with other opioids, the use of ciramadol can lead to a range of side effects. These can include drowsiness, nausea, constipation, and respiratory depression. In addition, like other opioids, ciramadol has the potential to cause physical dependence and addiction.

Legal Status

Ciramadol is a controlled substance in many countries, due to its potential for misuse and addiction. In the United States, it is classified as a Schedule II controlled substance, meaning it has a high potential for abuse and its use is strictly regulated.

See Also

• Opioid
• Tramadol
• Levorphanol
• Mu-opioid receptor

This article is a stub related to pharmacology. You can help WikiMD by expanding it!